MFT to use data to improve patient care through new ADAMS platform

Manchester University NHS Foundation Trust (MFT) is launching the MDClone Ask, Discover, Act, Measure and Share (ADAMS) platform in July, giving clinicians and approved teams easier access to data to support improvement, research and more informed care for patients. Its synthetic data capability will also reduce the need to use real patient data in many scenarios, supporting data safety and privacy.

The launch marks an important next step for the Trust as it builds on its strong track record in research, innovation and digital transformation. By making data easier to explore and use, the platform will help teams move more quickly from question to insight and identify opportunities to improve quality, productivity and performance.

Across the NHS, large volumes of data are generated, but it can still be difficult to access and use that information quickly enough to support improvement. The ADAMS platform will help clinicians identify and lead improvements in quality, productivity and performance with greater independence, helping teams respond faster to the issues that matter most to patients while working with data in a secure and appropriately governed way.

It will also support faster research by reducing the time it takes to move from a question to an insight. That will help clinicians, researchers and approved teams explore data more easily, support feasibility work, clinical audit and cohort building, and create stronger foundations for future research activity.

A third major benefit is safer collaboration. The ADAMS platform will help MFT work more safely and at a greater scale with approved academic and industry partners, enabling system-wide improvements. De-identified data remains an important and established way to protect privacy. The platform also generates high-fidelity synthetic data, reducing the need to use real patient data, and providing teams with additional privacy-enhancement to test ideas, explore research questions, develop methods, and collaborate.

The platform also includes AI-assisted analysis, helping approved users ask questions in plain English, explore data more easily and move faster from question to insight.

The platform will sit within MFT’s environment and governance framework, keeping data under NHS control and access limited to authorised users.

Professor David Walliker, Chief Digital and Information Officer, Manchester University NHS Foundation Trust, said: “The launch of the ADAMS platform is about giving our clinicians and teams better access to the data they need to improve care for patients. By making it easier for approved users to access and analyse data, it will help us identify opportunities to improve quality, productivity and performance more quickly and support faster research and innovation.

“The platform also strengthens our approach to data safety and privacy. ADAMS sits within MFT’s existing governance framework, keeping data under NHS control and access limited to authorised users. Its ability to generate high-fidelity synthetic data will reduce the need to use real patient data in many scenarios, providing an additional privacy-enhancing capability for improvement, research and collaboration.

“MFT already has a strong track record in digital innovation and data science. This platform builds on that foundation and will help us use data more effectively, support the safe development of AI, and ultimately improve care and outcomes for our patients.” 

Dr Anthony Wilson, Group Chief Medical Informatics Officer (Research and Innovation), MFT said: “For clinicians like me, the real benefit of this platform is that it allows healthcare professionals to go from an idea to an answer in a matter of minutes. We can use MFT’s data to better understand our patients’ healthcare journeys and identify opportunities to improve those journeys.

When the ADAMS platform goes live in July, our first area of focus will be kidney disease.  ADAMs will help us monitor our patients’ progress, improve our waiting lists and help to plan our kidney dialysis service across the Trust.

We are excited to see where ADAMS can take us and are looking forward to using data in a way that is more joined up, more timely and more directly relevant to improvement, research and collaboration.”

Bruno Lempernesse, Chief Executive Officer, MDClone, said: “MFT is joining other leading hospitals around the world that are using data more effectively to improve care, strengthen research and support safer collaboration. We are proud to partner with an organisation with MFT’s ambition and leadership as it builds long-term capability through the ADAMS platform.”